ReviewInternational journal of nanomedicine2026
Regulation of Mitochondrial Homeostasis: Applications of Nanobiomaterials in Age-Related Bone Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related bone diseases are a heterogeneous group of metabolic disorders characterized by progressive degenerative changes. Although nanobiomaterials have emerged as a promising means of regulation at the cellular level, their therapeutic efficacy remains very limited due to the lack of treatment strategies that directly target mitochondrial pathology. In recent years, nanobiomaterial therapies centered on mitochondria have attracted widespread attention. This review aims to critically evaluate the latest advances in this emerging field and categorize them into four main strategies: enhancing mitochondrial autophagy, optimizing the mitochondrial microenvironment, repairing mitochondrial structure, and implementing mitochondrial transfer therapy. Based on existing research, we have preliminarily established a multi-level intervention framework ranging from the clearance of dysfunctional mitochondria to the regulation of the microenvironment, and from the repair of structural components to the transplantation of healthy mitochondria, which has demonstrated encouraging proof-of-concept results in vitro and in animal models. However, this field remains in the preclinical exploration phase: the vast majority of studies are based on rodent models, the efficiency of mitochondrial-targeted delivery is generally low, and long-term biosafety and the feasibility of large-scale production have not yet been systematically evaluated. This review discusses the latest advances in mitochondrial-based nanobiomaterial therapies for age-related bone diseases. Furthermore, this review explores potential drugs and targets for the development of more effective nanobiomaterials, focusing on the key challenges facing the transition from the laboratory to clinical applications in this field, and is expected to provide novel insights into the future development of mitochondria-based nanobiomaterial therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.